Prothena | PRTA - 销售收入



金融业
股票价格
USD
资产
USD 302.58M
现金及等价物
USD 288.19M
销售成本
USD 28.94M
流动资产
USD 292.01M
流动负债
USD 11.66M
债务
USD 7.65M
EBIT
USD 25.79M
EBITDA
USD 25.98M
员工
163
EPS每股收益
USD 0.6
股本和储备
USD 286.89M
销售毛利
USD 51.08M
债务利息支出
USD 302.58M
利息收入
USD 2.42M
贷款资金
USD 0
市值
USD 458.8M
净收入
USD 32.72M
营业费用
USD 25.29M
营业利润
USD 25.79M
普通股股本
USD 53.08M
PE价格收益
22.11
税前利润
USD 32.72M
销售收入
USD 51.08M
销售和管理费用
USD 12.67M
贸易债权人
USD 1.94M
应收帐款人
USD 5.16M


销售 更改 日
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Akebia Therapeutics USD 57.62M 1.14M 2025-12
ALKERMES USD 496.01M 103.1M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Amgen USD 10.1B 1.48B 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Exelixis USD 628.69M 17.89M 2026-06
Incyte USD 1.67B 400M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
MacroGenics USD 20.8M 20.43M 2026-03
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 959M 148M 2026-06
Prothena USD 51.08M 51.06M 2026-03
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06